CONTINEUM THERAPEUTICS INC-A
CTNMNASDAQTrading Snapshot
- Day Range
- β
- 52-Week Range
- $6.73 β $17.79
- Volume (shares)
- β
- Avg Volume (shares)
- β
- Shares Outstanding
- 35.4M
- Next Earnings
- β
Fundamentals Snapshot
- Annual Revenue
- β
- Last Q Revenue
- β
- P/E Ratio
- -4.9
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-1.65
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +19.4%
CONTINEUM THERAPEUTICS INC-A
CTNMAbout CONTINEUM THERAPEUTICS INC-A
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The companyβs lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Latest News & Updates
News unavailable.